Apomorphine Nasal Powder in the Treatment of Parkinson's Disease Off Periods.

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00346827

Enrollment

Registered

2006-06-30

Start date

2006-07-31

Completion date

2007-08-31

Last updated

2019-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's Disease

Brief summary

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Interventions

DRUGApomorphine Nasal Powder

Study design

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Intervention model description

3-week, double-blind, placebo-controlled, 3 × crossover efficacy phase followed by 12 week open label phase, followed by 36 week open continuation phase

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* 1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented off period per day

Exclusion criteria

* hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026